What type of study is this?

This is a Pre-Registered Trial study.

December 5, 2025Blood AdvancesOpen Access

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML

View Full Paper

Ask AI

Bookmark

Authors

Phase 1 trial demonstrates 2-year OS of 77% in MDS/AML patients, suggesting efficacy of venetoclax maintenance with decitabine.

Median overall survival not reached at +25 months follow-up, indicating potential long-term benefit.
96% of patients experienced grade 3-4 neutropenia during maintenance therapy, while infections were rare.
Oral venetoclax and decitabine maintenance therapy provided promising outcomes in patients with poor-risk genetics.
Cumulative incidence of relapse was 38%, highlighting the need for ongoing treatment management.

Kim et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark